FDA Greenlights Mirdametinib in Adult and Pediatric NF1-PN
The FDA approved mirdametinib for the treatment of adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.
Related Articles
Clinical Case Evolution: Disease Progression Patterns After Initial Therapy
Panelists discuss how myelofibrosis can evolve following initial treatment, examining common patterns of disease progression and strategies for adapting therapeutic approaches based on individual patient…
Simplifying clinical use of TCGA molecular subtypes through machine learning models
In this issue of Cancer Cell, Ellrott et al. present machine learning models to classify samples into The Cancer Genome Atlas (TCGA) molecular subtypes using compact…
View From the Other Side of the Stethoscope: On Love &… : Oncology Times
An abstract is unavailable.
Protocol Reduces Side Effects Before Myeloma Transplant : Oncology Times
An abstract is unavailable.
Dr McNall-Knapp on HRQOL Outcomes With Mirdametinib in NF1-PN
Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.
2024 Hot Topic in Basic & Translational Science Conference Highlights | IASLC
IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will…
Welcome! You are invited to join a webinar: SSO CGSO Videoconference: Melanoma. After registering, you will receive a confirmation email about joining the webinar.
SSO sponsors educational videoconferences for CGSO Fellows, Residents, and faculty. This session will discuss the management of melanoma in both the localized and metastatic setting.…
Fox Chase Cancer Center’s Lilian J. Shin-Cho Selected as American Psychosocial Oncology Society 2025 Health Equity Scholar
PHILADELPHIA (January 31, 2025) — Lilian J. Shin-Cho, PhD, an Assistant Professor in the Cancer Prevention and Control Research Program at Fox Chase Cancer Center,…
Cytoreductive Therapy in PV Treatment Paradigm
Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which…
Getting the Full Story: The Importance of Ultra-Comprehensive Genomic Profiling in Advanced Cancer Therapy Selection
It’s difficult to imagine starting a cancer treatment path for a patient without first reviewing their molecular test results. This means getting the comprehensive story…